第二世代薬剤溶出ステント移植後の出血イベントの頻度と予測因子は移植後の期間に依存して異なる

Honda Yohsuke; Yamawaki Masahiro; Mori Shinsuke; Shirai Shigemitsu; Makino Kenji; Tokuda Takahiro; Maruyama Takashi; Takafuji Hiroya; Takama Takuro; Tsutumi Masakazu; Sakamoto Yasunari; Takimura Hideyuki; Kobayashi Norihiro; Araki Motoharu; Hirano Keisuke; Sakai Tsuyoshi; Ito Yoshiaki

文献

J-GLOBAL ID：201702234743059433 整理番号：17A0506768

第二世代薬剤溶出ステント移植後の出血イベントの頻度と予測因子は移植後の期間に依存して異なる

Frequency and predictors of bleeding events after 2nd generation drug-eluting stent implantation differ depending on time after implantation

出版者サイト {{ this.onShowPLink() }} 複写サービスで全文入手 {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=17A0506768&COPY=1") }}
高度な検索・分析はJDreamⅢで {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0506768&from=J-GLOBAL&jstjournalNo=W2218A") }}

著者 (17件)： , , , , , , , , , , , , , , , ,
資料名：
巻： 69 号： 4 ページ： 632-639 発行年： 2017年04月
JST資料番号： W2218A ISSN： 0914-5087 資料種別：逐次刊行物 (A)
記事区分：原著論文発行国：イギリス (GBR) 言語：英語 (EN)

背景:抗血小板療法は,薬剤溶出ステント(DES)移植後に必要...

,...
,...

続きはJDreamIII（有料）にて {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0506768&from=J-GLOBAL&jstjournalNo=W2218A") }}

著者キーワード (4件)： , , ,

術後処置・予後 , 循環系疾患の外科療法

引用文献 (35件)：

Gada, H., Kirtane, A.J., Newman, W., Sanz, M., Hermiller, J.B., Mahaffey, K.W., Cutlip, D.E., Sudhir, K., Hou, L., Koo, K., Stone, G.W. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial [clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions]. JACC Cardiovasc Interv. 2013;6:1263-6.
Kedhi, E., Gomes, M.E., Lagerqvist, B., Smith, J.G., Omerovic, E., James, S., Harnek, J., Olivecrona, G.K. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register. JACC Cardiovasc Interv. 2012;5:1141-9.
Stone, G.W., Rizvi, A., Sudhir, K., Newman, W., Applegate, R.J., Cannon, L.A., Maddux, J.T., Cutlip, D.E., Simonton, C.A., Sood, P., Kereiakes, D.J., SPIRIT IV Investigators. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT [Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System] IV trial. J Am Coll Cardiol. 2011;58:19-25.
Valgimigli, M., Tebaldi, M., Borghesi, M., Vranckx, P., Campo, G., Tumscitz, C., Cangiano, E., Minarelli, M., Scalone, A., Cavazza, C., Marchesini, J., Parrinello, G., PRODIGY Investigators. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study [PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY]. JACC Cardiovasc Interv. 2014;7:20-8.
Kimura, T., Morimoto, T., Nakagawa, Y., Tamura, T., Kadota, K., Yasumoto, H., Nishikawa, H., Hiasa, Y., Muramatsu, T., Meguro, T., Inoue, N., Honda, H., Hayashi, Y., Miyazaki, S., Oshima, S. et al, Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;119:987-95.

, , , , , ,

前のページに戻る